BLOKS(00325)

Search documents
港股新消费概念股午后走势分化,布鲁可(00325.HK)涨超24%,蜜雪集团(02097.HK)涨近7%,古茗(01364.HK)涨超5.5%,巨子生物(02367.HK)涨超4%,此前一度跌超4%,老铺黄金(06181.HK)跌近3%,沪上阿姨(02589.HK)跌1.3%。
news flash· 2025-06-09 05:44
Group 1 - The new consumption concept stocks in the Hong Kong market showed mixed performance in the afternoon session [1] - Bluetec (00325.HK) surged over 24%, indicating strong investor interest [1] - Mixue Group (02097.HK) rose nearly 7%, reflecting positive market sentiment [1] Group 2 - Gu Ming (01364.HK) increased by over 5.5%, suggesting a stable growth trend [1] - Giant Bio (02367.HK) saw a rise of over 4%, indicating resilience in its stock performance [1] - Lao Pu Gold (06181.HK) declined nearly 3%, showing some weakness in the market [1] Group 3 - Hu Shang Ayi (02589.HK) fell by 1.3%, indicating a slight downturn in its stock [1]
港股新消费概念股午后走势分化,布鲁可涨超25%,蜜雪集团涨近7%,古茗涨超5.5%,老铺黄金跌近3%,沪上阿姨跌1.3%。
news flash· 2025-06-09 05:44
港股新消费概念股午后走势分化,布鲁可涨超25%,蜜雪集团涨近7%,古茗涨超5.5%,老铺黄金跌近 3%,沪上阿姨跌1.3%。 ...
异动盘点0609|蜜雪、布鲁可、古茗今日入通;阿里影业再涨超16%;标普500季调维持成分股不变,HOOD、APP盘后下跌
贝塔投资智库· 2025-06-09 03:59
Core Viewpoint - The article highlights significant stock movements in the Hong Kong and US markets, indicating potential investment opportunities and sector trends, particularly in technology, healthcare, and entertainment sectors [1][2][3]. Hong Kong Market Highlights - Mixue (02097) surged over 7%, while Bluetec (00325) rose over 16%, and Guming (01364) increased over 3% [1]. - Lion Group (02562) gained over 4% as it plans to acquire a domestic SaaS company with substantial market share [1]. - Apple-related stocks saw a broad increase, with Sunny Optical (02382) up nearly 4%, and other companies like Q Tech (01478) and AAC Technologies (02018) rising over 3% [1]. - Far East Pharmaceutical (00512) rose over 3% as it commenced international Phase III clinical trials for its innovative ophthalmic drug CBT-001 [1]. - Alibaba Pictures (01060) jumped over 16%, with a cumulative increase of nearly 140% over the past two weeks, focusing on Damao performances and IP derivatives [1]. - Global Data (09698) increased over 5% after signing a strategic agreement with China Life Investment for comprehensive cooperation in asset securitization [1]. - Three Life Pharmaceuticals (01530) rose over 5% following a significant licensing agreement with Pfizer, showcasing promising data for SSGJ-707 [1]. - JD Group (09618) gained nearly 5% after signing a strategic cooperation agreement with China Resources Group [1]. - Tencent Music (01698) increased over 6% as it expands its international footprint by investing in South Korea's SM Entertainment [1]. - Cinda Biologics (01801) rose over 6% due to promising early data for IBI363 in lung cancer, with Goldman Sachs previously indicating the stock was undervalued [1]. - SMIC (00981) increased nearly 4% as it plans to sell its stake in SMIC Ningbo to focus on its core business [1]. - Rare earth stocks surged, with China Rare Earth (00769) up over 48% [1]. - Fubo Group (03738) rose over 3% after completing a 138 million share placement to enhance its AI business [1]. - Friendship Time (06820) surged over 22%, with a year-to-date increase exceeding 90%, driven by positive market feedback on its new game [1]. - Military stocks collectively rose, with China Shipbuilding Defense (00317) increasing nearly 4% [1]. US Market Highlights - Huaxing Capital Holdings (01911) surged over 14% following the successful listing of stablecoin "first stock" Circle, in which its fund participated in 2018 [2]. - In the US market, Circle's stock skyrocketed nearly 30% on its second day of trading after an initial 168% surge [2]. - Lululemon (LULU.US) fell nearly 20% after lowering its full-year profit guidance [2]. - DocuSign (DOCU.US) dropped nearly 19% after revising its full-year billing revenue forecast downward [2]. - Virgin Galactic (SPCE.US) rose over 2%, with a peak increase of over 14%, as it announced a potential recovery in commercial space flight services [2]. - Nvidia's holdings saw a broad increase, with Applied Digital (APLD.US) up over 8% and Recursion Pharmaceuticals (RXRX.US) rising over 20% [2]. - Robinhood (HOOD.US) fell 6.25% in after-hours trading, while AI stock Applovin (APP.US) dropped 5.53% [3].
深交所:深港通下的港股通标的调入布鲁可、古茗、蜜雪集团
news flash· 2025-06-09 02:45
深交所公告,因恒生综合中型股指数实施成份股调整,根据《深圳证券交易所深港通业务实施办法》的 有关规定,港股通标的证券名单发生调整,调入布鲁可、古茗、蜜雪集团,自2025年6月9日起生效。 ...
港股新消费概念股盘中持续走强,布鲁可(00325.HK)涨超16%,蜜雪集团(02097.HK)涨超8%,古茗(01364.HK)涨近4.5%,锅圈(02517.HK)、茶百道(02555.HK)涨超3.5%,泡泡玛特(09992.HK)涨1.8%。





news flash· 2025-06-09 02:16
Group 1 - The new consumption concept stocks in the Hong Kong market are showing strong performance, with notable increases in share prices [1] - Bruker (00325.HK) has surged over 16%, indicating significant investor interest [1] - Mixue Group (02097.HK) has risen more than 8%, reflecting positive market sentiment [1] Group 2 - Gu Ming (01364.HK) has increased nearly 4.5%, contributing to the overall strength of the sector [1] - Guoquan (02517.HK) and Cha Baidao (02555.HK) have both seen gains of over 3.5%, showcasing a broad-based rally [1] - Pop Mart (09992.HK) has experienced a rise of 1.8%, further highlighting the trend in new consumption stocks [1]

港股新消费概念股盘中持续走强,布鲁可涨超16%,蜜雪集团涨超8%,古茗涨近5%,锅圈、茶百道涨超3%,泡泡玛特涨近2%。
news flash· 2025-06-09 02:16
Group 1 - The new consumption concept stocks in the Hong Kong market are showing strong performance, with notable increases in share prices [1] - Blucco has risen over 16%, while Mixue Group has increased by more than 8% [1] - Other companies such as Guming, Guoquan, and Chabaidao have seen their stock prices rise by over 3%, and Pop Mart has increased by nearly 2% [1]
港股新消费概念股竞价活跃,泡泡玛特(09992.HK)涨超2.6%,蜜雪集团(02097.HK)、布鲁可(00325.HK)均涨超2%,茶百道(02555.HK)涨超1.8%。
news flash· 2025-06-09 01:29
Group 1 - The new consumption concept stocks in the Hong Kong market are actively trading, with notable increases in share prices for several companies [1] - Pop Mart (09992.HK) has seen a rise of over 2.6%, indicating strong market interest [1] - Other companies such as Mixue Group (02097.HK) and Blukoo (00325.HK) have also experienced increases of over 2%, while Cha Bai Dao (02555.HK) rose by more than 1.8% [1]
布鲁可(0325.HK)2025年中期策略会速递:稳步推新 迈向破圈 成长势能强劲
Ge Long Hui· 2025-06-06 18:01
Core Viewpoint - The company is expected to experience growth momentum in 2025 due to an accelerated pace of new product launches and a strong IP matrix, establishing a competitive moat in the market [1][2] Group 1: Product Launch and Market Strategy - Since March, the company has significantly increased its new product launch cadence, with several new products from major IPs like Kamen Rider, Naruto, Ultraman, Transformers, and Super Sentai being introduced [1] - The company has launched five products in the budget-friendly "Starry Version" series, which are expected to perform well due to their cost-effectiveness, contributing positively to the 2025 performance [1] - New products targeting adult fans and female demographics, such as Pokémon and Minions, have also been introduced, indicating a potential for expanding customer segments [1] Group 2: Overseas Expansion and Growth Potential - The company's overseas sales revenue increased by 518% year-on-year to 64 million yuan, with significant contributions from regions outside China, including Asia, North America, and others [2] - The company has showcased its products at various international toy fairs in Singapore, Germany, the USA, and Mexico, leveraging its competitive pricing and product features to connect with global fans [2] - Popular IPs like Ultraman and Transformers have received global licensing, indicating a strong potential for accelerated overseas business development in 2025 [2] Group 3: Financial Forecast and Valuation - The company maintains its profit forecast, expecting adjusted net profits of 1.181 billion, 1.814 billion, and 2.582 billion yuan for 2025-2027 [2] - Given the company's innovative "Brukoo System" and strong competitive barriers, the target price has been raised to 188 HKD, reflecting a 36x target PE for 2025 [2]
布鲁可:2025年中期策略会速递-稳步推新,迈向破圈,成长势能强劲-20250606
HTSC· 2025-06-06 09:40
Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 188.00 [9][10] Core Insights - The company has accelerated its product launch pace since March, introducing new products and IPs that are expected to contribute positively to growth in 2025 [2][4] - The establishment of the "Blokus System" creates competitive barriers through a standardized building block system, extensive patent layout, and a large, continuously expanding high-quality IP matrix [2][4] - The company aims for growth through a comprehensive approach targeting all demographics, price points, and global markets, indicating a clear growth trajectory [2][4] Summary by Sections Product Development and Market Expansion - The company has launched several new products in its main product line since March, including various iterations of popular IPs like Kamen Rider and Transformers [4] - The introduction of the Starry Edition series at a price point of HKD 9.9 has shown strong sales performance, expected to contribute significantly to 2025's revenue [4] - New products targeting adult fans and female demographics have also been introduced, indicating potential for market expansion [4] International Sales Growth - The company reported a 518% year-on-year increase in overseas sales revenue for 2024, reaching RMB 64 million, with significant contributions from Asia (excluding China) and North America [5] - Participation in international toy exhibitions has helped the company connect with global fans, and popular IPs have received licensing in multiple regions [5] Financial Projections and Valuation - The report maintains profit forecasts for 2025-2027, estimating adjusted net profits of RMB 11.81 billion, RMB 18.14 billion, and RMB 25.82 billion respectively [6] - The target price is based on a 36x PE ratio for 2025, reflecting the company's strong competitive position and growth potential [6][10] - Revenue projections show significant growth, with expected revenues of RMB 4.5 billion in 2025, up from RMB 2.24 billion in 2024 [8][19]
布鲁可(00325):2025年中期策略会速递:稳步推新,迈向破圈,成长势能强劲
HTSC· 2025-06-06 07:21
Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 188.00 [9][10] Core Insights - The company has accelerated its product launch pace since March, introducing new products and IPs that are expected to contribute positively to growth in 2025 [3][4] - The establishment of the "Blokus System" creates competitive barriers through a standardized building block system, extensive patent layout, and a large, continuously expanding high-quality IP matrix [3][4] - The company aims for growth through a comprehensive approach targeting all demographics, price points, and global markets, indicating a clear growth trajectory [3][4] Summary by Sections Product Development - The company has launched several new products in its main product line, including various iterations of popular IPs such as Kamen Rider, Naruto, Ultraman, and Transformers [4] - The introduction of the Starry Edition series at a price point of HKD 9.9 has shown strong sales performance, expected to contribute significantly to 2025's revenue [4] - New products targeting adult fans and female demographics have also been introduced, indicating potential for market expansion [4] International Expansion - The company reported a 518% year-on-year increase in overseas sales revenue, reaching RMB 64 million, with significant contributions from Asia (excluding China) and North America [5] - Participation in international toy exhibitions has helped the company connect with global fans, and popular IPs have received licensing in multiple regions [5] Financial Projections and Valuation - The report maintains profit forecasts for 2025-2027, estimating adjusted net profits of RMB 1.128 billion, RMB 1.772 billion, and RMB 2.564 billion respectively [6] - The target price is based on a 36x PE ratio for 2025, reflecting the company's strong competitive position and growth potential [6][10] - Revenue projections show significant growth, with expected revenues of RMB 4.499 billion in 2025, up from RMB 2.241 billion in 2024 [8][19]